Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

Research analysts at StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMDGet Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their price target on Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.

Check Out Our Latest Analysis on Aethlon Medical

Aethlon Medical Trading Down 2.3 %

AEMD opened at $1.72 on Thursday. The firm has a market cap of $4.51 million, a P/E ratio of -0.34 and a beta of 1.88. Aethlon Medical has a 12 month low of $1.40 and a 12 month high of $7.20. The stock has a 50-day moving average of $1.72 and a 200 day moving average of $1.83.

Aethlon Medical (NASDAQ:AEMDGet Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.14). On average, research analysts forecast that Aethlon Medical will post -4.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

Large investors have recently bought and sold shares of the business. HRT Financial LP bought a new position in Aethlon Medical in the fourth quarter worth approximately $28,000. Renaissance Technologies LLC raised its stake in Aethlon Medical by 61.4% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 38,264 shares in the last quarter. Two Sigma Investments LP bought a new position in Aethlon Medical in the third quarter worth approximately $32,000. Jane Street Group LLC raised its stake in Aethlon Medical by 895.7% in the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 126,160 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Aethlon Medical in the third quarter worth approximately $72,000. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Featured Stories

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.